Laboratory Report PID :
Name : Mrs BETHEL KALYANI Sex/Age : Female / 31 Years Lab ID : 50723002350
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Connect and Heal UHID :
Reg Dt. Time : 25-Jul-2025 11:41 Report Released @ : 25-Jul-2025 14:44 Sample Type : Whole Blood EDTA
Sample Dt. Time : 25-Jul-2025 11:41 Report Printed @ : 25-Jul-2025 19:59
TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS
HAEMOGRAM REPORT
HB AND INDICES
Haemoglobin 14.9 G% 12.0 - 15.0
Photometric Method
RBC (Electrical Impedance) H 5.05 millions/cum 3.80 - 4.80
m
PCV(Calc) 43.33 % 36.00 - 46.00
MCV (RBC histogram) 85.8 fL 83.00 - 101.00
MCH (Calc) 29.5 pg 27.00 - 32.00
MCHC (Calc) 34.3 gm/dL 31.50 - 34.50
RDW (RBC histogram) 11.60 % 11.00 - 16.00
TOTAL AND DIFFERENTIAL WBC COUNT (Flowcytometry)
Total WBC Count 8,490 /µL 4000.00 - 10000.00
Neutrophil 59 % 40.00 - 70.00
Lymphocyte 31 % 20.00 - 40.00
Eosinophil 02 % 1.00 - 6.00
Monocytes 08 % 2.00 - 10.00
Basophil 00 % 0.00 - 2.00
Neutrophil 5009 /µL 2000.00 - 7000.00
Calculated
Lymphocyte 2632 /µL 1000.00 - 3000.00
Calculated
Eosinophil 170 /µL 20.00 - 500.00
Calculated
Monocyte 679 /µL 200.00 - 1000.00
Calculated
Basophil 0 /µL 0.00 - 100.00
Calculated
PLATELET COUNT(Optical)
Platelet Count 2,01,000 /µL 150000.00 - 410000.00
Neut/Lympho Ratio (NLR) 1.90 0.78 - 3.53
CALC
Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)
Dr. Ankita Srivastava
DNB PATHOLOGY
TSMC/FMR/23216
Page 1 of 8
Laboratory Report PID :
Name : Mrs BETHEL KALYANI Sex/Age : Female / 31 Years Lab ID : 50723002350
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Connect and Heal UHID :
Reg Dt. Time : 25-Jul-2025 11:41 Report Released @ : 25-Jul-2025 14:44 Sample Type : Whole Blood EDTA
Sample Dt. Time : 25-Jul-2025 11:41 Report Printed @ : 25-Jul-2025 19:59
SMEAR STUDY
RBC Morphology Normocytic
Normochromic RBCs.
WBC Morphology Total WBC count within
normal limits.
Platelet Platelets are adequate
in number.
Parasite Malarial Parasite not
seen on smear.
Morphological Impression Normal study for the
given age group
ESR 10 mm after 1hr 3 - 20
Westergren Method
Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)
Dr. Ankita Srivastava
DNB PATHOLOGY
TSMC/FMR/23216
Page 2 of 8
Laboratory Report PID :
Name : Mrs BETHEL KALYANI Sex/Age : Female / 31 Years Lab ID : 50723002350
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Connect and Heal UHID :
Reg Dt. Time : 25-Jul-2025 11:41 Report Released @ : 25-Jul-2025 14:44 Sample Type : Serum
Sample Dt. Time : 25-Jul-2025 11:41 Report Printed @ : 25-Jul-2025 19:59
TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS
BUN (Blood Urea Nitrogen) 8.5 mg/dL 7.0 - 17.0
Dry Chemistry
Uric Acid 3.86 mg/dL 2.6 - 6.0
Uricase-Peroxidase method
Creatinine 0.82 mg/dL 0.50 - 1.00
Enzymatic
TSH L 0.36 µIU/mL 0.38 - 5.33
Chemiluminescence Immunoassay
INTERPRETATIONS
• Circulating TSH measurement has been used for screening for euthyroidism, screening and diagnosis for
hyperthyroidism & hypothyroidism. Suppressed TSH (<0.01 µIU/mL) suggests a diagnosis of hyperthyroidism
and elevated concentration (>7 µIU/mL) suggest hypothyroidism. TSH levels may be affected by acute illness
and several medications including dopamine and glucocorticoids. Decreased (low or undetectable) in Graves
disease. Increased in TSH secreting pituitary adenoma (secondary hyperthyroidism), PRTH and in
hypothalamic disease thyrotropin (tertiary hyperthyroidism). Elevated in hypothyroidism (along with decreased
T4) except for pituitary & hypothalamic disease.
• Mild to modest elevations in patient with normal T3 & T4 levels indicates impaired thyroid hormone reserves &
incipent hypothyroidism (subclinical hypothyroidism).
• Mild to modest decrease with normal T3 & T4 indicates subclinical hyperthyroidism.
• Degree of TSH suppression does not reflect the severity of hyperthyroidism, therefore, measurement of free
thyroid hormone levels is required in patient with a supressed TSH level.
CAUTIONS
Sick, hospitalized patients may have falsely low or transiently elevated thyroid stimulating hormone.
Some patients who have been exposed to animal antigens, either in the environment or as part of treatment or
imaging procedure, may have circulating antianimal antibodies present. These antibodies may interfere with the
assay reagents to produce unreliable results.
TSH ref range in pregnancy Reference range (microIU/ml)
First trimester 0.24 - 2.00
Second trimester 0.43-2.2
Third trimester 0.8-2.5
Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)
J ANJAIAH Dr. Ankita Srivastava
DNB PATHOLOGY
TSMC/FMR/23216
Page 3 of 8
Verified by
Laboratory Report PID :
Name : Mrs BETHEL KALYANI Sex/Age : Female / 31 Years Lab ID : 50723002350
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Connect and Heal UHID :
Reg Dt. Time : 25-Jul-2025 11:41 Report Released @ : 25-Jul-2025 14:44 Sample Type : Serum
Sample Dt. Time : 25-Jul-2025 11:41 Report Printed @ : 25-Jul-2025 19:59
TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS
VITAMIN D
25 OH Cholecalciferol (D2+D3) 32.3 ng/mL Deficient : <20
Chemiluminescence Immunoassay Insufficient : 20-30
Sufficient : 30-100
Upper Safety Limit : >100
25-OH-VitD plays a primary role in the maintenance of calcium homeostasis. It promotes intestinal calcium absorption and, in concert with PTH, skeletal calcium
deposition, or less commonly, calcium mobilization. Modest 25-OH-VitD deficiency is common; in institutionalised elderly, its prevalence may be >50%. Although much
less common, severe deficiency is not rare either. Reasons for suboptimal 25-OH-VitD levels include lack of sunshine exposure, a particular problem in Northern latitudes
during winter; inadequate intake; malabsorption (e.g, due to Celiac disease); depressed hepatic vitamin D 25-hydroxylase activity, secondary to advanced liver disease;
and enzyme-inducing drugs, in particular many antiepileptic drugs, including phenytoin, phenobarbital, and carbamazepine, that increase 25-OH-VitD metabolism.
Hypervitaminosis D is rare, and is only seen after prolonged exposure to extremely high doses of vitamin D. When it occurs, it can result in severe hypercalcemia and
hyperphosphatemia.
INTERPRETATION
Levels <10 ng/mL may be associated with more severe abnormalities and can lead to inadequate mineralization of newly formed osteoid, resulting in rickets in children
and osteomalacia in adults. In these individuals, serum calcium levels may be marginally low, and parathyroid hormone (PTH) and serum alkaline phosphatase are usually
elevated. Definitive diagnosis rests on the typical radiographic findings or bone biopsy/histomorphometry.
Patients who present with hypercalcemia, hyperphosphatemia, and low PTH may suffer either from ectopic, unregulated conversion of 25-OH-VitD to 1,25 (OH)2-VitD, as
can occur in granulomatous diseases, particularly sarcoidosis, or from nutritionally-induced hypervitaminosis D. Serum 1,25 (OH)2-VitD levels will be high in both groups,
but only patients with hypervitaminosis D will have serum 25-OH-VitD concentrations of >80 ng/mL, typically >150 ng/mL.
Patients with CKD have an exceptionally high rate of severe vitamin D deficiency that is further exacerbated by the reduced ability to convert 25-OH- VitD into the active
form, 1,25 (OH)2-VitD. Emerging evidence also suggests that the progression of CKD & many of the cardiovascular complications may be linked to hypovitaminosis D.
Approximately half of Stage 2 and 3 CKD patients are nutritional vitamin D deficient (25-OH-VitD, less than 30 ng/mL), and this deficiency is more common among stage 4
CKD patients. Additionally, calcitriol (1,25 (OH)2-VitD) levels are also overtly low (less than 22 pg/mL) in CKD patients. Similarly, vast majority of dialysis patients are found
to be deficient in nutritional vitamin D and have low calcitriol levels. Recent data suggest an elevated PTH is a poor indicator of deficiencies of nutritional vitamin D and
calcitriol in CKD patients.CAUTIONS Long term use of anticonvulsant medications may result in vitamin D deficiency that could lead to bone disease; the anticonvulsants
most implicated are phenytoin, phenobarbital, carbamazepine, and valproic acid.
Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)
J ANJAIAH Dr.Kishan
MD (Pathology)
Verified by Page 4 of 8
Laboratory Report PID :
Name : Mrs BETHEL KALYANI Sex/Age : Female / 31 Years Lab ID : 50723002350
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Connect and Heal UHID :
Reg Dt. Time : 25-Jul-2025 11:41 Report Released @ : 25-Jul-2025 14:44 Sample Type : Plasma Fluoride F,Whole
Blood EDTA
Sample Dt. Time : 25-Jul-2025 11:41 Report Printed @ : 25-Jul-2025 19:59
TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS
Plasma Glucose - F 84.73 mg/dL 70-110
GOD-POD
Glycated Haemoglobin Estimation
HbA1C 5.2 % Non Diabetic : < 6.0 %
HPLC Pre Diabetic : 6.0 -
6.4 %
Diabetic : => 6.5
%.
Estimated Avg Glucose (3 Mths) 102.54 mg/dL Not available
Calculated
Interpretation :
HbA1C level reflects the mean glucose concentration over previous 8-12 weeks and provides better indication of long term glycemic control.
Levels of HbA1C may be low as result of shortened RBC life span in case of hemolytic anemia.
Increased HbA1C values may be found in patients with polycythemia or post splenectomy patients.
Patients with Homozygous forms of rare variant Hb(CC,SS,EE,SC) HbA1c can not be quantitated as there is no HbA.
In such circumstances glycemic control can be monitored using plasma glucose levels or serum Fructosamine.
The A1c target should be individualized based on numerous factors, such as age, life expectancy,comorbid conditions, duration of diabetes,
risk of hypoglycemia or adverse consequences from hypoglycemia, patient motivation and adherence.
Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)
J ANJAIAH Dr. Ankita Srivastava
DNB PATHOLOGY
TSMC/FMR/23216
Page 5 of 8
Verified by
Laboratory Report PID :
Name : Mrs BETHEL KALYANI Sex/Age : Female / 31 Years Lab ID : 50723002350
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Connect and Heal UHID :
Reg Dt. Time : 25-Jul-2025 11:41 Report Released @ : 25-Jul-2025 13:21 Sample Type : Serum
Sample Dt. Time : 25-Jul-2025 11:41 Report Printed @ : 25-Jul-2025 19:59
TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS
BIOCHEMICAL INVESTIGATIONS
Lipid Profile
Cholesterol 187.7 mg/dL <200 - Desirable
Colorimetric, CHOD-PAP 200 - 239 - Borderline High
> 240 - High
"NCEP Guidelines ATP III".
HDL Cholesterol 55.1 mg/dL < 40 - Low Level
Direct Method 40 - 60 - Average Level
> 60 - High Level
NCEP Guidelines ATP III.
Triglyceride H 152.56 mg/dL <150
GPO-POD
VLDL 30.51 mg/dL 10 - 40
Calculated
Chol/HDL 3.41 0 - 4.1
Calculated
LDL Cholesterol H 102.09 mg/dL 0.00 - 100.00
Calculated
Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)
T.SHIVAJI Dr. Ankita Srivastava
DNB PATHOLOGY
TSMC/FMR/23216
Page 6 of 8
Verified by
Laboratory Report PID :
Name : Mrs BETHEL KALYANI Sex/Age : Female / 31 Years Lab ID : 50723002350
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Connect and Heal UHID :
Reg Dt. Time : 25-Jul-2025 11:41 Report Released @ : 25-Jul-2025 13:21 Sample Type : Serum
Sample Dt. Time : 25-Jul-2025 11:41 Report Printed @ : 25-Jul-2025 19:59
TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS
BIOCHEMICAL INVESTIGATIONS
Liver Function Test
S.G.P.T. 14.21 10-35
IFCC
S.G.O.T. 13.13 U/L 5-34
IFCC
Alkaline Phosphatase 70.72 IU/L 0-105
Photometry
Gamma Glutamyl Transferase 30.19 U/L 5-36
IFCC
Proteins (Total) 6.06 g/L 6.0 -8.2
Biuret
Albumin 3.56 gm/dL 3.5-5.0
Bromocresol purple
Globulin 2.50 gm/dL 2 - 4.1
Calculated
A/G Ratio 1.42 1.0 - 2.1
Calculated
Bilirubin Total 0.47 mg/dL 0.3 - 1.2
Diazonium Salt
Bilirubin Conjugated 0.12 mg/dL 0-0.3
Bilirubin Unconjugated 0.35 mg/dL 0 - 0.8
Calculated
Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)
T.SHIVAJI Dr. Ankita Srivastava
DNB PATHOLOGY
TSMC/FMR/23216
Page 7 of 8
Verified by
Laboratory Report PID :
Name : Mrs BETHEL KALYANI Sex/Age : Female / 31 Years Lab ID : 50723002350
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Connect and Heal UHID :
Reg Dt. Time : 25-Jul-2025 11:41 Report Released @ : 25-Jul-2025 14:48 Sample Type : Serum
Sample Dt. Time : 25-Jul-2025 11:41 Report Printed @ : 25-Jul-2025 19:59
TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS
Vitamin B - 12 Level 194 pg/mL Normal : 180-914
Chemiluminescence Immunoassay Indeterminate : 145-180
Deficient : <145
Introduction :
Vitamin B12, a member of the corrin family, s a cofactor for the formation of myelin, and along with folate, is required for DNA synthesis. Levels above 300 or 400 are
rarely associated with B12 deficiency induced hematological or neurological disease.
Clinical Significance :
Causes of Vitamin B12 deficiency can be divided into three classes: Nutritional, malabsorption syndromes and gastrointestinal causes. B12 deficiency can cause
Megaloblastic anemia (MA), nerve damage and degeneration of the spinal cord. Lack of B12 even mild deficiencies damages the myelin sheath. The nerve damage
caused by a lack of B12 may become permanently debilitating.
The relationship between B12 and MA is not always clear that some patients with MA will have normal B12 levels; conversely, many individuals with B12 deficiency are
not afflicted with MA.
Decreased in:
Iron deficiency, normal near-term pregnancy, vegetarianism, partial gastrectomy/ileal damage, celiac disease, use of oral contraception, parasitic competition, pancreatic
deficiency, treated epilepsy and advancing age.
Increased in:
Renal failure, liver disease and myeloproliferative diseases.
Variations due to age Increases: with age.
Temporarily Increased after Drug.
Falsely high in Deteriorated sample.
Pending Services ------------------ End Of Report ------------------
ECG
Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)
J ANJAIAH Dr.Kishan
MD (Pathology)
Verified by Page 8 of 8
